Akouos (Akouos) Net Change in Cash : $-39.21 Mil (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Akouos Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Akouos's Net Change in Cash for the three months ended in Sep. 2022 was $1.83 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 was $-39.21 Mil.

Akouos Net Change in Cash Historical Data

The historical data trend for Akouos's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos Net Change in Cash Chart

Akouos Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Net Change in Cash

17.58

2.06

43.85

54.11

Akouos Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Change in Cash	Get a 7-Day Free Trial											-16.69	7.28	-67.53	19.20	1.83

Akouos Net Change in Cash Calculation

Akouos's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-63.733	+	117.622	+	0.217	+	0
	=	54.11

Akouos's Net Change in Cash for the quarter that ended in Sep. 2022

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -21.1 + 22.963 + -0.029 + 0

= 1.83

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akouos Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Akouos's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Akouos (Akouos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Net Change in Cash

Comparable Companies

PBYI TRVI OTLC ARDX HOOK BCAB SRZN ADVM MRZM FBIO OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 200, Boston, MA, USA, 02210

Website

https://www.akouos.com

Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.

Executives

Kearny Acquisition Corp 10 percent owner LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285

Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285

Jennifer Anne Wellman officer: Chief Operating Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210

Sachiyo Minegishi officer: Chief Financial Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210

5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025

Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025

Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025

Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025

Pivotal Bioventure Partners Fund I G.p., L.p. 10 percent owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107

New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093

Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093

Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103

Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116

Heather Preston director, 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102

Akouos (Akouos) Headlines

From GuruFocus

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
By GuruFocusNews GuruFocusNews • 06-28-2022

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
By GuruFocusNews GuruFocusNews • 05-29-2022

AKUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akouos, Inc. Is Fair to Shareholders
By Business Wire Business Wire • 10-18-2022

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
By GuruFocusNews GuruFocusNews • 06-18-2022

SHAREHOLDER ALERT: Weiss Law Investigates Akouos, Inc.
By PRNewswire PRNewswire • 10-21-2022

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
By PRNewswire PRNewswire • 12-01-2022

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
By GuruFocusNews GuruFocusNews • 06-08-2022

Thinking about buying stock in Akouos, Federated National, Bright Minds Biosciences, VNET Group, or MFA Financial?
By PRNewswire PRNewswire • 10-18-2022

Shareholder Alert: Ademi LLP investigates whether Akouos, Inc. has obtained a Fair Price in its transaction with Eli Lilly
By PRNewswire PRNewswire • 10-18-2022

Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights
By GuruFocusNews GuruFocusNews • 06-01-2022

Kearny Acquisition Corp	10 percent owner	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman	officer: Chief Operating Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi	officer: Chief Financial Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi	10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p.	10 percent owner	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston	director, 10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102